Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies

Metastatic basal cell cancer (BCC) is an ultra-rare malignancy with no approved therapies beyond Hedgehog inhibitors. We characterized the genomics, tumor mutational burden (TMB), and anti-PD-1 therapy responses in patients with locally advanced or metastatic BCC. Overall, 2,039 diverse cancer sampl...

Descripción completa

Detalles Bibliográficos
Autores principales: Goodman, Aaron M., Kato, Shumei, Cohen, Philip R., Boichard, Amélie, Frampton, Garrett, Miller, Vincent, Stephens, Philip J., Daniels, Gregory A., Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790366/
https://www.ncbi.nlm.nih.gov/pubmed/29399405
http://dx.doi.org/10.1080/2162402X.2017.1404217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790366/
https://www.ncbi.nlm.nih.gov/pubmed/29399405
http://dx.doi.org/10.1080/2162402X.2017.1404217

Ejemplares similares